"Antibodies, Monoclonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies produced by a single clone of cells.
| Descriptor ID |
D000911
|
| MeSH Number(s) |
D12.776.124.486.485.114.224 D12.776.124.790.651.114.224 D12.776.377.715.548.114.224
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal".
This graph shows the total number of publications written about "Antibodies, Monoclonal" by people in this website by year, and whether "Antibodies, Monoclonal" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 7 | 16 | 23 |
| 1996 | 4 | 11 | 15 |
| 1997 | 4 | 7 | 11 |
| 1998 | 6 | 16 | 22 |
| 1999 | 10 | 18 | 28 |
| 2000 | 7 | 12 | 19 |
| 2001 | 14 | 20 | 34 |
| 2002 | 11 | 14 | 25 |
| 2003 | 15 | 15 | 30 |
| 2004 | 23 | 16 | 39 |
| 2005 | 25 | 19 | 44 |
| 2006 | 26 | 15 | 41 |
| 2007 | 30 | 13 | 43 |
| 2008 | 21 | 21 | 42 |
| 2009 | 31 | 19 | 50 |
| 2010 | 38 | 22 | 60 |
| 2011 | 19 | 12 | 31 |
| 2012 | 17 | 11 | 28 |
| 2013 | 18 | 9 | 27 |
| 2014 | 17 | 12 | 29 |
| 2015 | 13 | 7 | 20 |
| 2016 | 15 | 6 | 21 |
| 2017 | 27 | 10 | 37 |
| 2018 | 22 | 14 | 36 |
| 2019 | 18 | 10 | 28 |
| 2020 | 14 | 13 | 27 |
| 2021 | 10 | 17 | 27 |
| 2022 | 4 | 19 | 23 |
| 2023 | 2 | 8 | 10 |
| 2024 | 15 | 5 | 20 |
| 2025 | 5 | 3 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Monoclonal" by people in Profiles.
-
Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn's disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY). J Crohns Colitis. 2025 Jun 04; 19(6).
-
Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study. Future Oncol. 2025 May; 21(12):1511-1523.
-
Mapping the extracellular molecular architecture of the pAg-signaling complex with a-Butyrophilin antibodies. Sci Rep. 2025 Apr 09; 15(1):12162.
-
Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2025 May; 26(5):596-608.
-
Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis. J Crohns Colitis. 2025 Apr 04; 19(4).
-
Distinguishing Daratumumab from Endogenous Monoclonal Proteins in Serum from Multiple Myeloma Patients Using an Automated Mass Spectrometry System. J Appl Lab Med. 2025 Mar 03; 10(2):235-249.
-
Production and characterization of monoclonal antibodies against hepatitis B e-antigen and their potential application for development of HBeAg detection ELISA. Biologicals. 2025 May; 90:101819.
-
Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies. J Crohns Colitis. 2025 Jan 11; 19(1).
-
Mutability and hypermutation antagonize immunoglobulin codon optimality. Mol Cell. 2025 Jan 16; 85(2):430-444.e6.
-
Novel Antibody-Based Protection/Therapeutics in Staphylococcus aureus. Annu Rev Microbiol. 2024 Nov; 78(1):425-446.